孙涛涛, 胡志辉, 王淑侠. 18F-FDG PET/CT诊断早期骨髓浸润的临床价值[J]. 循证医学, 2015, 15(6): 358-362. DOI: 10.3969/j.issn.1671-5144.2015.06.012
    引用本文: 孙涛涛, 胡志辉, 王淑侠. 18F-FDG PET/CT诊断早期骨髓浸润的临床价值[J]. 循证医学, 2015, 15(6): 358-362. DOI: 10.3969/j.issn.1671-5144.2015.06.012
    SUN Tao-tao, HU Zhi-hui, WANG Shu-xia. Clinical Value of 18F-FDG PET/CT in Diagnosis of Early Bone Marrow Infiltration[J]. Journal of Evidence-Based Medicine, 2015, 15(6): 358-362. DOI: 10.3969/j.issn.1671-5144.2015.06.012
    Citation: SUN Tao-tao, HU Zhi-hui, WANG Shu-xia. Clinical Value of 18F-FDG PET/CT in Diagnosis of Early Bone Marrow Infiltration[J]. Journal of Evidence-Based Medicine, 2015, 15(6): 358-362. DOI: 10.3969/j.issn.1671-5144.2015.06.012

    18F-FDG PET/CT诊断早期骨髓浸润的临床价值

    Clinical Value of 18F-FDG PET/CT in Diagnosis of Early Bone Marrow Infiltration

    • 摘要: 目的 探讨骨髓高代谢病变18F-FDG PET/CT的诊断价值。 方法 分析2010年7月至2015年6月在广东省人民医院进行18F-FDG PET/CT检查并提示骨髓弥漫性高代谢。其余部位未见恶性肿瘤代谢影像的62例病例,分别对PET、CT、PET/CT 融合图像与病理或随访结果进行对照分析。 结果 62例患者的PET/CT影像表现为全身骨骼及骨髓系统放射性药物摄取弥漫性增高,以脊柱、胸骨、髂骨等为著,CT 异常9例,表现为骨质密度斑片状弥漫性增高/减低、病理示良性病变35例,其中骨髓反应性增生15例、骨髓增生大致正常14例、骨髓增生稍活跃6例;恶性病变27例,其中淋巴瘤侵犯骨髓14例、各种白血病11例、MDS 2例、恶性病变组SUVmax为(7.2±2.4),高于良性组的(5.2±1.8),差异有统计学意义(t=3.89,P=0.000)。根据全部病变的SUVmax值绘制受试者工作特征曲线,曲线下的面积为0.757,P=0.001,Youden Index最大时(0.532),SUVmax=6.25。以SUVmax=6.25为阈值,18F-FDG PET/CT检查对62例骨髓高代谢病变良恶性鉴别诊断的敏感度、特异度、准确度分别为70.4%、82.9%、77.4%。 结论 PET对骨髓恶性病变的早期诊断具有一定的临床价值,骨髓弥漫性高代谢病变值得进一步活检。

       

      Abstract: Objective To investigate the diagnostic value of 18F-FDG PET/CT in bone marrow which appears high metabolism. Methods 62 18F-FDG PET/CT image cases were analyzed from July 2010 to June 2015 in our hospital, which bone marrow showed diffuse high metabolism, and the remaining parts of the image presented no malignant metabolic. PET, CT and PET/CT fusion images were compared with the pathology or follow-up results, respectively. Results The PET/CT images of 62 patients showed diffuse increase in FDG uptake of whole-body bone and bone marrow system, in the spine, sternum, ilium as the significant. The CT abnormality was 9 cases, which showed a diffuse increase or decrease of bone density. Pathological examination showed benign lesions was 35 cases and reactive bone marrow hyperplasia was found in 15 cases, bone marrow hyperplasia roughly normal in 14 cases, bone marrow hyperplasia slightly active in 6 cases. Malignant lesion was found in 27 patients, including lymphoma bone marrow involvement in 14 cases, different types of leukemia in 11 cases, MDS in 2 cases. The SUVmax of malignant lesion was (7.2±2.4), which was more than (5.2±1.8) of benign groups (t was 3.89, P was 0.000), and the difference was statistically significant. According to the SUVmax to get ROC curve, the area under the curve was 0.757, P was 0.001. When Youden Index was max (0.532), SUVmax was 6.25. Using 6.25 as the threshold value, for 18F-FDG PET/CT showing high metabolism with bone marrow, in these 62 cases, the sensitivity, specificity and accuracy of PET in differential diagnosis of benign and malignant were 70.4%, 82.9% and 77.4%. Conclusions PET has a considerable clinical value for early diagnosis of bone marrow malignant lesions, and it is worthy of further biopsy of bone marrow in PET diffuse high metabolic lesions.

       

    /

    返回文章
    返回